Stryker Corporation Reports 11.1% Revenue Growth in Q2 2025, Acquires Inari Medical

Stryker Corporation reported strong financial performance for the second quarter of 2025, with net sales reaching $6.022 billion, an increase of 11.1% compared to $5.422 billion in the same period of 2024. For the first half of 2025, the company achieved net sales of $11.888 billion, up from $10.665 billion in the prior year, marking an 11.5% growth. The gross profit for the second quarter was $3.841 billion, representing a gross margin of 63.8%, slightly up from 63.0% in the previous year. However, net earnings for the quarter increased to $884 million, or $2.29 per diluted share, a rise from $825 million, or $2.14 per diluted share, in the prior year. For the six-month period, net earnings decreased to $1.538 billion, or $3.98 per diluted share, down from $1.613 billion, or $4.19 per diluted share, in 2024.

The company experienced notable changes in its operational structure, including the acquisition of Inari Medical, Inc. for approximately $4.810 billion, which was completed in February 2025. This acquisition is expected to enhance Stryker's Vascular business within its MedSurg and Neurotechnology segment. Additionally, Stryker restructured its Spine business, reclassifying certain product lines to better align with its internal reporting structure. The company also reported a significant increase in selling, general, and administrative expenses, which rose by 13.5% in the second quarter, primarily due to higher acquisition-related costs and investments in growth.

Stryker's operational metrics showed positive trends, with increased unit volumes across most product lines contributing to sales growth. The MedSurg and Neurotechnology segment reported a 17.3% increase in net sales for the second quarter, while the Orthopaedics segment saw a more modest growth of 2.0%. The company also noted that its international sales grew by 6.8% in the second quarter, indicating successful geographic expansion. The total employee headcount remained stable, with 382.3 million shares of common stock outstanding as of June 30, 2025.

The filing indicated that Stryker's effective tax rate decreased to 13.0% for the second quarter, down from 17.3% in the previous year, largely due to a tax benefit related to the sale of its Spinal Implants business. The company also reported cash provided by operating activities of $1.361 billion for the first half of 2025, a significant increase from $837 million in the same period of 2024. However, cash used in investing activities surged to $4.240 billion, primarily due to the Inari acquisition.

Looking ahead, Stryker remains optimistic about its growth trajectory, driven by ongoing product innovation and strategic acquisitions. The company anticipates continued sales growth in both its MedSurg and Neurotechnology and Orthopaedics segments, despite potential challenges posed by macroeconomic factors such as tariffs and inflation. Stryker's management emphasized their commitment to enhancing healthcare outcomes through innovative medical technologies, positioning the company for sustained success in the competitive medical device market.